• About us
• Contact

Advertisement

Product › Details

TissueSpan implants

	Next higher product group	tissue engineering / regenerative medicine_oo
	Status	2024-07-22 development existent
	Organisation	Regenosca SA

Regenosca SA. (7/22/24). "Press Release: Regenosca Closes CHF 1M Pre-seed Round to Demonstrate Endoscopic Delivery of TissueSpan Implants". Lausanne.

Regenosca creates unique bio-implants, enabling the body to attract and organise its own cells for seamless healing. Providing a temporary, naturally absorbed bridge, the TissueSpan technology replaces diseased tissue and restores patients to full health.

With access to markets worth up to $5bn annually for Regenosca’s regenerative medicine platform, the initial application is urethral stricture (narrowing), affecting up to a million patients a year in the U.S. The current gold-standard procedure involves open surgery and the harvesting of a patient's own inner mouth tissue for grafting. Simpler endoscopic treatments have up to 80% failure rates. The company has already performed human trials with perfect regrowth of the patients’ own tissue.

Regenosca has successfully raised CHF 1 million from private investors, Business Angels Switzerland, and Venture Kick. “This funding will allow us to demonstrate endoscopic delivery of TissueSpan”, said Eva-Maria Balet, CEO and co-founder. “This new approach will revolutionise the treatment of urethral stricture. An off-the-shelf implant instead of the patient’s own tissue. A simple endoscopic procedure instead of complex open surgery.”

Prof Philippe Sèbe, urologist at Hôpitaux Universitaires Genève (HUG) and clinical development partner with Regenosca on the endoscopic technology, emphasises: “TissueSpan implants represent a great opportunity, opening up a significant new area of development in urethral repair surgery.”

Preclinical data and successful completion of the first human trials show promising market traction, winning awards at the three biggest urology conferences globally: the European Association of Urology, the Société Internationale d’Urologie, and the American Urological Association.
 
Recognising the generous support received to date from Innosuisse, the Gebert Rüf Foundation, and Venture Kick, Regenosca proudly welcomes this new group of investors.


About:

Regenosca (www.regenosca.com) is a regenerative medtech firm based in Lausanne that provides seamless tissue regeneration to solve today’s difficult clinical problems in a surgeon- and patient-friendly way.


Contact:

Dr Eva-Maria Balet
+41 78 868 79 73
[email protected]

Record changed: 2024-07-24

Advertisement

More documents for tissue engineering / regenerative medicine

• [1] Tenpoint Therapeutics Ltd.. (7/12/23). "Press Release: Tenpoint Therapeutics Launches with $70 Million Series A Financing to Reverse Vision Loss Through Engineered Cell-based Therapeutics and In Vivo Reprogramming". London....
• [2] DiogenX SAS. (5/10/23). "Press Release: DiogenX Raises €27.5M Series A Financing to Advance Its First-in-Class Regenerative Treatment for Type 1 Diabetes Towards Clinical Development". Marseille....
• [3] Forever Healthy Foundation gGmbH. (9/15/22). "Press Release: Rejuvenation Startup Summit 2022 Announces Program and Speakers"....
• [4] Forever Healthy Foundation gGmbH. (5/19/22). "Press Release: Rejuvenation Startup Summit Premieres October, 14-15, 2022 in Berlin"....
• [5] Mogrify Ltd.. (10/5/21). "Press Release: Mogrify Strengthens Executive Leadership Team with the Appointment of Louise Modis as Chief Scientific Officer". Cambridge....
• [6] Fresenius Medical Care AG & Co. KGaA. (8/30/21). "Press Release: Fresenius Medical Care Increases Investment in Humacyte, Accompanies Human Acellular Vessel Developer’s Stock Market Launch"....
• [7] Humacyte, Inc.. (8/26/21). "Press Release: Humacyte Announces Successful Closing of Business Combination with Alpha Healthcare Acquisition Corp.". Durham, NC....
• [8] Mimetas B.V.. (7/6/21). "Press Release: Mimetas and Roche Enter into a Collaboration to Develop Human Disease Models for Drug Development". Leiden....
• [9] Humacyte, Inc.. (2/17/21). "Press Release: Humacyte, a Transformative Biotechnology Platform Company Capable of Manufacturing Universally Implantable Bioengineered Human Tissue at Commercial Scale, Going Public via Merger with Alpha Healthcare Acquisitio...
• [10] Evonik Industries AG. (3/17/20). "Press Release: Evonik Achieves Major Biotech Breakthrough with a New Animal-free and Fermentation-based Collagen Platform"....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.